Stemedica - Model itMSCs - Ischemia-Tolerant Mesenchymal Stem Cells
itMSCs (ischemia-tolerant mesenchymal stem cells) are “trophic” cells that circulate throughout the body and release proteins and growth factors into the damaged tissue, rescuing damaged cells from death and creating the right conditions for the newly mobilized cells to proliferate and repair. Stemedica’s itMSCs are extracted from donated bone marrow and then expanded using our proprietary technology.
-
Most popular related searches
itNSCs (ischemia-tolerant neural stem cells) are m...
itNSCs (ischemia-tolerant neural stem cells) are mostly undifferentiated, multipotent cells that generate the main phenotypes of cells in the nervous system. Stemedica’s itNSCs are extracted from donated brain tissue and then expanded using our proprietary technology.
Stemedica manufactures itMSCs and itNSCs for use in FDA-approved clinical trials in the U.S. Additionally, we supply our progenitor cells to geographic distributors to conduct clinical trials that are approved by international regulatory agencies, and for research through our exclusive distribution partner, ThermoFisher Scientific.
The distinctive properties of Stemedica’s itMSCs and itNSCs include the following attributes:
Ischemia tolerant: Stemedica’s progenitor cells are manufactured in hypoxic environment to combat ischemic conditions. For example, itMSCs secrete larger amounts of important cytokines, such as VEGF and SDF-1, that enhance the healing process. VEGF is critical for new blood vessel growth and SDF-1 helps mobilize the patient’s own progenitor cells.
Immune privileged: Stemedica’s progenitor cells do not exhibit HLA-DR antigen proteins which may cause rejection. The lack of HLA-DR expression for each batch is confirmed by flow cytometry analysis. No immunosuppressant agents are required during treatment.
Documented safety: The cells undergo rigorous testing for endogenous viruses, adventitious agents, bacteria, mycoplasma and endotoxin, as well as acute and chronic toxicity and tumorigenicity.
Established purity: Stemedica maintains rigorous specifications for each of the appropriate biological markers that indicate cell purity. Furthermore, extensive batch testing indicates lot-to-lot reproducibility.
Verified potency: For progenitor cells to be effective in vivo, they must secrete the appropriate growth factors, cytokines and hormones. The progenitor cells must also demonstrate the ability to differentiate into specific types of tissues, such as bone, neurons or cartilage. Stemedica ensures that its progenitor cells meet required criteria prior to release for clinical use.
Customer reviews
No reviews were found for Stemedica - Model itMSCs - Ischemia-Tolerant Mesenchymal Stem Cells. Be the first to review!